Shots:
- Abcuro has reported the P-II/III (MUSCLE) trial data assessing ulviprubart (ABC008; Q8W) in 272 IBM pts randomized to either 0.5mg/kg (n=94, Low Dose), 2mg/kg (n=92, High Dose), or PBO (n=86)
- Across all pts, the 1EP showed a trend toward slower IBMFRS decline at Wk. 76, with a 1.7-point decrease in the low-dose group vs 2.4 with PBO, while the high-dose group showed a 2.1-point decline, indicating limited overall treatment effect
- In pts with baseline IBMFRS ≥29, trial showed a trend toward slower decline over 76wks., with a 1.3-point decrease for both doses vs 2.6, indicating ~50% slowing of disease progression. Abcuro to discuss next steps with the FDA to advance ulviprubart in IBM
Ref: Businesswire | Image: Abcuro | Press Release
Related News: Otsuka Pharmaceutical Reports P-III (VISIONARY) Trial Data on Voyxact for IgA Nephropathy (IgAN)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
